SYK

Represents shares of Common Stock gifted by the Reporting Person to a charitable donor advised fund.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2026.

The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $305.59 to $305.665, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2026.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2026.

The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $307.06 to $307.76, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2026.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2026.

The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $306.05 to $306.945, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2026.

The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $308.78 to $308.79, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $313.00 to $313.985, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $311.00 to $311.998, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $314.00 to $314.985, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $310.35 to $310.995, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $315.00 to $315.69, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.

Includes 679,642 shares previously held by the L. Lee Stryker Trust which were transferred to the Revocable Trust on May 28, 2026.

The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $312.00 to $312.995, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.

These shares, which were previously owned directly, were transferred to the Living Trust on March 26, 2026.

Employee stock option granted pursuant to the Stryker Corporation 2011 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant.

Employee stock option granted pursuant to the Stryker Corporation 2011 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant.

Includes 128 shares of Stryker Common Stock acquired pursuant to Stryker Corporation's Employee Stock Purchase Plan ("ESPP") as of March 31, 2026, the date of the latest available statement of the reporting person's ESPP holdings.

Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027. The Reporting Person voluntarily elected to defer receipt of the shares of Stryker Common Stock issuable upon settlement of the RSUs until May 1, 2031.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Represents a grant of Restricted Stock Units (RSUs) pursuant to the Stryker 2011 Long-Term Incentive Plan, which vest as follows: one-third of the shares on May 1, 2027; one-third of the shares on May 1, 2028; and the remaining one-third of the shares on May 1, 2029.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Represents a grant of Restricted Stock Units (RSUs) pursuant to the Stryker 2011 Long-Term Incentive Plan, which vest as follows: one-third of the shares on May 1, 2027; one-third of the shares on May 1, 2028; and the remaining one-third of the shares on May 1, 2029.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027. The Reporting Person voluntarily elected to defer receipt of the shares of Stryker Common Stock issuable upon settlement of the RSUs until his departure from the Board of Directors.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027.

Each RSU represents a contingent right to receive one share of Stryker Common Stock.

On March 11, 2026, the Reporting Person filed a Form 4 reporting the acquisition of 14,912 shares of Stryker Common Stock earned upon the satisfaction of certain performance criteria, subject to vesting on March 21, 2026 (the "Performance Stock Units"). The 430 shares being reported here represent dividend equivalents issued in connection with the earned Performance Stock Units, which also vested on March 21, 2026 and were settled for an equal number of shares of Stryker Common Stock.

On March 11, 2026, the Reporting Person filed a Form 4 reporting the acquisition of 5,220 shares of Stryker Common Stock earned upon the satisfaction of certain performance criteria, subject to vesting on March 21, 2026 (the "Performance Stock Units"). The 150 shares being reported here represent dividend equivalents issued in connection with the earned Performance Stock Units, which also vested on March 21, 2026 and were settled for an equal number of shares of Stryker Common Stock.

On March 11, 2026, the Reporting Person filed a Form 4 reporting the acquisition of 9,320 shares of Stryker Common Stock earned upon the satisfaction of certain performance criteria, subject to vesting on March 21, 2026 (the "Performance Stock Units"). The 269 shares being reported here represent dividend equivalents issued in connection with the earned Performance Stock Units, which also vested on March 21, 2026 and were settled for an equal number of shares of Stryker Common Stock.

Includes 185 shares of Stryker Common Stock acquired pursuant to Stryker Corporation's Employee Stock Purchase Plan ("ESPP") and 27 shares pursuant to the Performance Incentive Award ("PIA") Plan as of December 31, 2025, the date of the latest available statement of the reporting person's ESPP and PIA holdings.

On March 11, 2026, the Reporting Person filed a Form 4 reporting the acquisition of 7,828 shares of Stryker Common Stock earned upon the satisfaction of certain performance criteria, subject to vesting on March 21, 2026 (the "Performance Stock Units"). The 225 shares being reported here represent dividend equivalents issued in connection with the earned Performance Stock Units, which also vested on March 21, 2026 and were settled for an equal number of shares of Stryker Common Stock.

On March 11, 2026, the Reporting Person filed a Form 4 reporting the acquisition of 14,912 shares of Stryker Common Stock earned upon the satisfaction of certain performance criteria, subject to vesting on March 21, 2026 (the "Performance Stock Units"). The 430 shares being reported here represent dividend equivalents issued in connection with the earned Performance Stock Units, which also vested on March 21, 2026 and were settled for an equal number of shares of Stryker Common Stock.

On March 11, 2026, the Reporting Person filed a Form 4 reporting the acquisition of 50,332 shares of Stryker Common Stock earned upon the satisfaction of certain performance criteria, subject to vesting on March 21, 2026 (the "Performance Stock Units"). The 1,452 shares being reported here represent dividend equivalents issued in connection with the earned Performance Stock Units, which also vested on March 21, 2026 and were settled for an equal number of shares of Stryker Common Stock.

On March 11, 2026, the Reporting Person filed a Form 4 reporting the acquisition of 14,912 shares of Stryker Common Stock earned upon the satisfaction of certain performance criteria, subject to vesting on March 21, 2026 (the "Performance Stock Units"). The 430 shares being reported here represent dividend equivalents issued in connection with the earned Performance Stock Units, which also vested on March 21, 2026 and were settled for an equal number of shares of Stryker Common Stock.

On March 11, 2026, the Reporting Person filed a Form 4 reporting the acquisition of 9,320 shares of Stryker Common Stock earned upon the satisfaction of certain performance criteria, subject to vesting on March 21, 2026 (the "Performance Stock Units"). The 269 shares being reported here represent dividend equivalents issued in connection with the earned Performance Stock Units, which also vested on March 21, 2026 and were settled for an equal number of shares of Stryker Common Stock.

On March 11, 2026, the Reporting Person filed a Form 4 reporting the acquisition of 14,912 shares of Stryker Common Stock earned upon the satisfaction of certain performance criteria, subject to vesting on March 21, 2026 (the "Performance Stock Units"). The 430 shares being reported here represent dividend equivalents issued in connection with the earned Performance Stock Units, which also vested on March 21, 2026 and were settled for an equal number of shares of Stryker Common Stock.

On March 11, 2026, the Reporting Person filed a Form 4 reporting the acquisition of 7,828 shares of Stryker Common Stock earned upon the satisfaction of certain performance criteria, subject to vesting on March 21, 2026 (the "Performance Stock Units"). The 225 shares being reported here represent dividend equivalents issued in connection with the earned Performance Stock Units, which also vested on March 21, 2026 and were settled for an equal number of shares of Stryker Common Stock.